High-Intensity Interval Nordic Walking for Coronary Artery Disease
(HIIT-NoW Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to help individuals with coronary artery disease feel better after heart procedures like bypass surgery or stent placement. It tests whether a workout combining high-intensity exercises with Nordic walking (using specially designed poles) can improve physical and mental health. Participants will either engage in this new workout, known as high-intensity interval Nordic walking, or follow standard heart rehab exercises. Ideal candidates have coronary artery disease, have undergone heart procedures, and are willing to participate in exercise sessions. As an unphased trial, this study provides a unique opportunity to explore innovative exercise methods that could enhance recovery and overall well-being.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that high-intensity interval Nordic walking (HIIT-NoW) is safe for individuals with coronary artery disease. Studies have found that exercise programs like HIIT-NoW are manageable and can enhance both physical and mental health. Importantly, this type of exercise carries a low risk of serious heart problems. Thus, it provides an effective workout while prioritizing heart safety.12345
Why are researchers excited about this trial?
High-intensity interval Nordic walking is unique because it combines the benefits of aerobic exercise with the added resistance of walking poles, which helps engage more muscle groups. Unlike standard cardiovascular rehabilitation programs that often include moderate exercise routines, this method introduces short bursts of intense activity, potentially offering more significant improvements in cardiovascular fitness. Researchers are excited about this approach because it could enhance heart health and physical endurance more effectively than traditional rehab exercises, providing an innovative way to help those with coronary artery disease.
What evidence suggests that high-intensity interval Nordic walking is effective for coronary artery disease?
Research has shown that high-intensity interval Nordic walking (HIIT-NoW), a treatment in this trial, can greatly benefit people with coronary artery disease (CAD). Studies have found that 12 weeks of this exercise can improve heart and lung health and enhance quality of life. This walking style uses poles, engaging both the upper and lower body, and has been shown to safely boost physical and mental well-being. It also helps burn more calories while being gentle on the knees. Participants in this trial will either engage in HIIT-NoW or undergo standard cardiovascular rehabilitation, both of which have been shown to improve physical and mental health in people with CAD.12346
Who Is on the Research Team?
Jennifer L Reed, PhD
Principal Investigator
Ottawa Heart Institute Research Corporation
Are You a Good Fit for This Trial?
This trial is for patients at least 40 years old with coronary artery disease who have had a stent inserted or heart bypass surgery. They must be willing to attend exercise sessions on-site, able to perform an exercise test measuring heart and lung function, and not currently in cardiac rehab.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo high-intensity interval Nordic walking training or standard cardiovascular rehabilitation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- High-intensity interval Nordic walking
- Standard cardiovascular rehabilitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Heart Institute Research Corporation
Lead Sponsor